Point72 Asset Management
INO icon

Point72 Asset Management’s Inovio Pharmaceuticals INO Stock Holding History

Point72 Asset Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,674
Closed -$31.2K – 2442
2023
Q3 		$31.2K Buy
6,674
+3,774
+130% +$20.8K ﹤0.01% 2215
2023
Q2 		$15.5K Sell
2,900
-4,213
-59% -$34K ﹤0.01% 1839
2023
Q1 		$70K Buy
+7,113
New +$121K ﹤0.01% 1707

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management's INO Position: Q4 2023 in Review

Point72 Asset Management sold out of Inovio Pharmaceuticals (INO) in Q4 2023, closing a stake of 6,674 shares — an estimated $31.2K sold.

Point72 Asset Management first reported a position in INO in Q1 2023 and held it in 3 quarters. The position peaked at $70K in Q1 2023. 113 funds tracked by Wall St. Rank hold INO as of Q4 2023.

  • Point72 Asset Management reported no remaining Inovio Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Point72 Asset Management sold 6,674 Inovio Pharmaceuticals shares in Q4 2023, an estimated $31.2K.
  • Point72 Asset Management first reported a position in Inovio Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Point72 Asset Management's Inovio Pharmaceuticals position peaked at $70K in Q1 2023.
  • 113 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.